Traditional antiviral therapies target one virus-type at a time
OUR APPROACH IS DIFFERENT
There are only twenty or so viruses we can defend against in a pandemic, leaving hundreds of viral infections that have no cure at all. The challenge with traditional antivirals and vaccines is they can only target one virus-type at a time and cannot defend against a virus’ ability to quickly evolve and develop drug-resistance.
Evrys Bio takes a different approach. Unlike traditional therapies, Evrys Bio antivirals target non-viral human proteins, known as sirtuins, enhancing their natural ability to fight powerful infections. Because sirtuins broadly affect different viruses, Evrys Bio antivirals address the multitude of viruses that can cause a given infectious disease condition. For example, our vision is that an Evrys Bio product will address viral hepatitis that can be caused by either hepatitis B virus or hepatitis C virus. Current products can only address one or the other, not both viruses. Furthermore, because sirtuins are non-viral human proteins, viruses cannot develop drug-resistance against sirtuin-targeted drugs, transforming the way we treat and cure viral infections today .
Actualizing Innovation. A proven team advancing today’s innovation into tomorrow’s transformative therapeutics.
Next Gen Antivirals that engage the patient’s own immunity to naturally defend against viral infection without the emergence of drug resistance.
Transformative Achievements. Evrys Bio in the News.